Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
NASDAQ
EPS improving
EPS improving
226M
Biotechnology
Next Earning date - 12 Nov 2024
226M
Biotechnology
Next Earning date - 12 Nov 2024
Relative Strenght
74Volume Buzz
-22%Earning Acce
YesDist 52w H.
17%